Fulcrum Therapeutics (NASDAQ:FULC) Receives Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC - Free Report) in a report issued on Thursday,Benzinga reports. They currently have a $4.00 price target on the stock.

A number of other analysts have also recently issued reports on the company. Bank of America cut Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Royal Bank of Canada cut Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their target price for the stock from $15.00 to $4.00 in a report on Thursday, September 12th. Leerink Partners reiterated a "market perform" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Stifel Nicolaus cut Fulcrum Therapeutics from a "buy" rating to a "hold" rating and decreased their price target for the stock from $22.00 to $3.00 in a report on Thursday, September 12th. Finally, Leerink Partnrs cut Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics has a consensus rating of "Hold" and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ:FULC traded down $0.24 during trading on Thursday, reaching $3.32. 653,734 shares of the stock were exchanged, compared to its average volume of 988,940. Fulcrum Therapeutics has a 12-month low of $2.87 and a 12-month high of $13.70. The firm has a market cap of $207.17 million, a price-to-earnings ratio of -10.84 and a beta of 2.24. The firm's 50-day moving average price is $3.97 and its 200 day moving average price is $6.53.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Fulcrum Therapeutics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company's stock valued at $23,965,000 after purchasing an additional 18,681 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Fulcrum Therapeutics by 13.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company's stock valued at $9,182,000 after purchasing an additional 176,114 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Fulcrum Therapeutics by 223.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company's stock valued at $2,032,000 after purchasing an additional 393,202 shares in the last quarter. Jane Street Group LLC raised its position in shares of Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company's stock valued at $5,051,000 after acquiring an additional 188,212 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Fulcrum Therapeutics during the 2nd quarter valued at approximately $3,084,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.